ArticleFrontiers in oncology2025
Identification of key molecular targets for stachyose in hepatocellular carcinoma: focus on STAT3 and FN1.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Hepatocellular carcinoma (HCC) ranks among the most prevalent malignancies on a global scale. Stachyose (STA), an oligosaccharide widely present in legumes, has demonstrated various biological activities, including improving gut microbiota, anti-oxidative stress, and anti-tumor proliferation. This study aimed to predict potential targets of STA in HCC treatment and to identify key hub genes. Methods: By integrating multiple public databases and bioinformatics tools, we screened 34 candidate targets and constructed STA's action network and PPI network in HCC. Functional enrichment analysis revealed 10 relevant KEGG pathways and key features related to cellular components, molecular functions, and biological processes. Finally, we conducted molecular docking, single gene analysis, and Results: Through screening of multiple databases, we identified 34 common targets associated with STA and HCC and subsequently constructed a protein-protein interaction (PPI) network. Through this analysis, we ultimately selected STAT3 and FN1 as core hub genes. Functional and pathway analyses indicated that these targets participate in multiple cancer-related pathways and have significant roles in cellular components, biological processes, and molecular functions. The results indicated a positive correlation between the expression of STAT3 and FN1 with angiogenesis, tumor inflammation, and epithelial-mesenchymal transition (EMT). Molecular docking experiments validated the stable binding capacity between STA and these core genes, and Conclusion: This study offers a comprehensive exploration of the molecular mechanisms through which STA may treat HCC, identifying STAT3 and FN1 as key targets and validating their clinical relevance and potential for application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.